Amgen paying $24.9M to settle Aranesp kickback allegations
This article was originally published in Scrip
Executive Summary
Amgen agreed to pay the US $24.9 million to settle allegations the Thousand Oaks, California-based biotech giant violated the False Claims Act by paying kickbacks to three long-term care pharmacies for switching Medicare and Medicaid beneficiaries from a competitor drug to the company's erythropoiesis-stimulating agents (ESAs) Aranesp (darbepoetin alfa).